Homeowners Battle Insurers Over $2.9 Trillion Climate Risk
When Bernard Weisse first noticed a tiny crack in the outer wall of his house on the outskirts of Paris, he dismissed it as little more than a nuisance. But in the four years since, a spiderweb of fissures has spread from floor to ceiling and snaked into virtually every corner of his home.
'We can hear loud cracking noises especially when it's warm outside,' said the retired salesman and father of three. 'Sometimes, I think we should get all our stuff together and leave.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Dozens more Palestinians killed by Israeli fire as war drags on
Israeli strikes and gunfire in the Gaza Strip have killed at least 46 Palestinians overnight into Wednesday morning, most of them among crowds seeking food, hospitals said. The dead include more than 30 people who were seeking humanitarian aid, according to a hospital that treated dozens of wounded people. The Israeli military did not immediately comment on any of the strikes, but says it only targets militants and blames civilian deaths on Hamas, because the group's militants operate in densely populated areas. The deaths came as the UK announced it would recognise a Palestinian state in September, unless Israel agrees to a ceasefire in the Israel-Hamas war, after a similar declaration by France's president. Israel's foreign ministry said that it rejected the British statement. The Shifa hospital in Gaza City said it received 12 people who were killed on Tuesday night when Israeli forces opened fire towards crowds waiting for aid trucks coming from the Zikim crossing in north-western Gaza. Thirteen others were killed in strikes in the Jabaliya refugee camp and the northern towns of Beit Lahiya and Beit Hanoun, the hospital said. In the southern city of Khan Younis, the Nasser hospital said it received the bodies of 16 people it says were killed on Tuesday evening while waiting for aid trucks close to the newly built Morag corridor, which separates Khan Younis from the southernmost city of Rafah. The hospital received another body, of a man killed in a strike on a tent in Khan Younis, it said. The Awda hospital in the urban Nuseirat refugee camp said that it received the bodies of four Palestinians who it says were killed on Wednesday by Israeli fire close to an aid distribution site run by the Gaza Humanitarian Foundation (GHF) in the Netzarim corridor area, south of the Wadi Gaza. Seven more Palestinians, including a child, have died of malnutrition-related causes in the Gaza Strip in the past 24 hours, the territory's health ministry said on Wednesday. A total of 89 children have died of malnutrition since the war began in Gaza. The ministry said 65 Palestinian adults have also died of malnutrition-related causes across Gaza since late June, when it started counting deaths among adults. Hamas started the war with a militant-led attack on southern Israel on October 7 2023, killing around 1,200 people and abducting 251 others. They still hold 50 hostages, though Israel believes that more than half are dead. Most of the rest were released in ceasefires or other deals. Israel's retaliatory offensive has killed more than 60,000 Palestinians, according to Gaza's Health Ministry. Its count doesn't distinguish between militants and civilians. The ministry operates under the Hamas government. The UN and other international organisations see it as the most reliable source of data on casualties.
Yahoo
18 minutes ago
- Yahoo
Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress
LONDON and PHILADELPHIA, July 30, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing innovative, targeted oncology drugs, today announces that the Company will present an updated data analysis from the Phase 1a trial of FAP-Dox (AVA6000) at the 2025 European Society for Medical Oncology (ESMO) Congress, in Berlin, Germany, taking place from October 17-21, 2025. AVA6000 is a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by FAP in the tumor microenvironment. The poster presentation will be based on the most recent data analysis from the Phase 1a trial of FAP-Dox (AVA6000) in patients with Fibroblast Activation Protein (FAP)-positive solid tumors. Avacta completed the Phase 1a enrollment dose escalation portion of the clinical trial in late 2024, with patient enrollment ongoing in multiple dose expansion cohorts of a Phase 1b study. Abstract details are listed below and available online on the ESMO website. Avacta will hold an investor event shortly after the ESMO presentation. Further details will be made available nearer the time. Title: A Phase I trial of FAP-Dox (AVA6000), a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumorsSession Title: Developmental TherapeuticsSession Date and Time: 17 October, 19:40 - 20:00Location: Berlin Auditorium - Hub 27Abstract Presentation Number: 964PSpeaker: William D. Tap For further information from Avacta, please contact: Avacta Group plcMichael Vinegrad, Group CommunicationsDirector Peel Hunt (Nomad and Joint Broker)James Steel / Chris Golden Panmure Liberum (Joint Broker)Emma Earl / Will Goode / Mark Rogers Zeus (Joint Broker)James Hornigold / George DuxberryDominic King ICR Healthcare (Europe/UK media and investors)Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert avacta@ Investor ContactRenee Leck THRUST Strategic Communications renee@ Media ContactCarly ScadutoCarly Scaduto Consulting Carly@ About Avacta - Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates. About the pre|CISION® PlatformThe pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.
Medscape
19 minutes ago
- Medscape
Cannabis and Lung Cancer: A Link Stronger Than It Appears
The toxicity of cannabis, particularly its potential link to lung cancer, has long been underestimated. However, recent studies are challenging this 'false innocence,' identifying a growing population of younger patients with high cannabis consumption who are presenting with aggressive cancers. Pauline Pradère, MD, pulmonologist at Marie Lannelongue Hospital in Paris, France, and a leading researcher on this topic, discussed the effects of cannabis on lung health during this year's ALBATROS International Addictology Congress. Inhaled Cannabis Use 'France holds the unfortunate distinction of being the leading cannabis consumer in Europe,' said Pradère. In 2019, it was estimated that by the time they turned 17, 1 in 5 French individuals had consumed cannabis at least once in the past month. Most of this consumption is through inhalation of cannabis resin joints, often mixed with tobacco. Given the high prevalence, it is crucial to understand the potential impact of cannabis on respiratory health. While many studies focus on the neuropsychological effects of cannabis, Pradère emphasized that its inhalation, which introduces the substance directly into the lungs, may have significant pulmonary effects — effects that remain under-researched, particularly regarding lung cancer risk. Cannabis and Lung Cancer Pradère referenced a well-known study published in Chest in 2018, which suggested that smoking cannabis does not cause emphysema or impair inspiratory function. Although biopsies of cannabis smokers showed precancerous lesions, the study did not strongly connect these findings to lung cancer. Another 2018 meta-analysis, often cited to 'clear' cannabis consumption of lung cancer risk, concluded that there were insufficient data to draw definitive conclusions. Pradère criticized this study for not specifically examining cannabis use and its unique effects. While evidence links cannabis consumption to an increased risk for testicular tumors, the connection to lung cancer remains unclear. A recent review published in The New England Journal of Medicine also examines the chronic effects of cannabis, focusing primarily on its neuropsychiatric impact. However, the review makes no mention of its effects on the lungs, noted the pulmonologist. Additionally, there are other studies that highlight the potential therapeutic properties of cannabis in cancer care, such as managing cancer-related symptoms, treatment-associated pain, and even its possible antitumor effects. One such article, provocatively titled Can Cannabis Cure Cancer? , further fuels the debate surrounding cannabis' medical use. Stronger Evidence for Harmful Effects Despite the conflicting data, several factors suggest a harmful role of chronic cannabis inhalation in lung health. The first is a toxicologic argument. 'Even without considering the resin and tobacco association, significant carcinogens are found in joints,' explained Pradère. The second argument, recognized by those with asthma, is that tetrahydrocannabinol, the psychoactive component of cannabis, has a bronchodilatory effect, likely leading to deeper inhalation of carcinogens than with tobacco smoking. Histologic studies have shown that cannabis smokers develop precancerous lesions similar to those found in tobacco smokers. These findings further suggest a possible link between cannabis use and lung cancer. Epidemiologic Data While research remains limited, Pradère highlighted epidemiologic studies that suggest cannabis use is a risk factor for lung cancer. A Canadian study, for example, showed that cannabis use reported at the age of 20 years significantly affected the later development of lung cancer. Adolescents who smoked more than 50 joints during their teenage years were found to have more than double the risk of developing bronchial carcinoma. Why the Discrepancy? To explain the reassuring findings in some meta-analyses, Pradère pointed to challenges in studying the link between chronic cannabis use and lung cancer. She noted that many cannabis users also smoke tobacco, and in France, the illegal status of cannabis leads to the addition of other substances to cannabis resin, further complicating research. Additionally, a significant underreporting of cannabis use by patients contributes to these gaps in data, especially when clinicians fail to directly ask about cannabis use. This underreporting is one of the reasons Pradère pursued her research in this area. Pradère works at a center specializing in lung cancer surgery, where she has observed a high prevalence of cannabis use among patients. Over 3 years, she studied patients younger than 50 years who had undergone lung cancer surgery at three major hospitals in the Île-de-France region. She then followed up with these patients post-surgery to gather more information about their cannabis consumption. Study on 75 Patients Younger Than 50 Years 'We contacted 75 patients who had undergone surgery for lung cancer over 3 years, and none of them refused to participate,' Pradère explained. 'We found that 43% of our young patients were chronic cannabis users.' On average, these patients smoked 150 joints per month, and for 61% of them, no healthcare provider had ever asked about their cannabis use. 'They had seen general practitioners, anesthesiologists, surgeons, and pulmonologists, but no one had ever asked,' she added. When comparing the three patient groups — those who smoked both cannabis and tobacco, those who smoked only tobacco, and nonsmokers — the results showed that the cannabis-smoking group, which represented a significant proportion, was predominantly men. Their tobacco consumption was similar to those who smoked only tobacco. However, they presented with more emphysema and poor prognosis carcinomas, such as poorly differentiated large cell carcinomas. 'The tumors were more often located in the upper lobes, where the majority of inhaled toxins concentrate. Additionally, their surgery durations and hospital stays were longer, likely due to underlying lung damage,' Pradère pointed out. Prospective Study of 150 Patients Building on her earlier work, Pradère led a multicenter prospective study, supported by the French National Cancer Institute, which included 150 patients younger than 60 years diagnosed with primary lung cancer. 'We collaborated with the Toxicology Department, led by Jean-Claude Alvarez, MD, PhD, at Garches University Hospital, where we conducted toxicological analyses on patients' hair and administered anonymous self-report questionnaires outside the medical office,' Pradère explained. The study aimed to evaluate both the prevalence of cannabis consumption among these patients and whether the lung cancer of cannabis smokers differed from that of tobacco smokers. Though the manuscript is still under review, Pradère shared some preliminary findings. 'We observed a high prevalence of cannabis use in this group of young patients with highly lethal lung cancer. 38% were cannabis smokers, with an average consumption of four joints per day over a median period of 26 years.' Lung conditions among cannabis smokers included more emphysema, including bullous emphysema, which increases the risk for pneumothorax. Pulmonary function tests revealed greater damage in gas diffusion than in tobacco smokers, even though their exposure to tobacco was similar. The study also found that cannabis smokers had a higher incidence of poor prognosis cancers, such as poorly differentiated carcinomas and sarcomatoid carcinomas. New Perspectives and Concerns Pradère emphasized that her research aligns with recent studies in France, such as the KBP study, which has increasingly focused on the potentially harmful effects of cannabis. However, she believes pulmonologists have not fully addressed the issue and that many still struggle to provide clear guidance to patients on cannabis-related health risks, including how to manage cannabis withdrawal — often a more challenging process than quitting tobacco. 'I believe this is an area where we must make progress within the medical community,' she concluded.
